---
title: "Pre-market hot trades in US stocks: Check Cap pre-market down 7.76%; ChowChow Cloud pre-market down 3.06%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257921343.md"
description: "Check Cap pre-market down 7.76%; ChowChow Cloud pre-market down 3.06%; 89bio pre-market up 86.88%; Aptevo Therap pre-market up 74.40%; Datavault AI pre-market up 38.69%"
datetime: "2025-09-18T12:32:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257921343.md)
  - [en](https://longbridge.com/en/news/257921343.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257921343.md)
generator: "portal-rs"
---

# Pre-market hot trades in US stocks: Check Cap pre-market down 7.76%; ChowChow Cloud pre-market down 3.06%

**Pre-market Hot Trades in US Stocks**

Check Cap is down 7.76% in pre-market. Based on recent key news:

1.  On September 15, Check-Cap announced a merger agreement with MBody AI, leading to a significant increase in stock price. MBody AI focuses on the development of autonomous intelligent systems, with a projected market size reaching $40 trillion by 2050. This news triggered a strong market reaction, with trading volume surging to 67 million shares, far exceeding the three-month daily average of 1 million shares. Sources: News 1, 2, 3. The merger agreement has attracted market attention.

ChowChow Cloud is down 3.06% in pre-market. Based on recent key news:

1.  On September 17, ChowChow Cloud announced the pricing of its initial public offering (IPO). The company completed an IPO of 2,990,000 shares at a price of $4.00 per share. This news caused fluctuations in market demand for the stock, affecting its price. Source: Reuters. The market's response to the IPO has been mixed, leading to increased volatility.

**Top Gainers in Pre-market US Stocks**

89bio is up 86.88% in pre-market. Based on recent important news:

1.  On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This news propelled 89bio's stock price significantly higher in pre-market trading. Data source: Zhitong Finance.

2.  On September 18, 89bio's key drug pegozafermin is considered a potential best therapy for treating MASH, enhancing market confidence in its future potential. Data source: Zhitong Finance.

3.  On September 18, 89bio's board unanimously approved the acquisition agreement, further solidifying market expectations for the completion of the deal. Data source: MarketBeat. The biopharmaceutical industry is active in mergers and acquisitions, leading to increased market volatility.

Aptevo Therapeutics is up 74.40% in pre-market. Based on recent important news:

1.  On September 16, Aptevo Therapeutics announced that its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate in the third cohort, resulting in a 57% increase in stock price. The trial tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients.

2.  On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months, indicating a strong market reaction to the company's news.

3.  On September 17, despite facing financial performance challenges, including declining revenue and high leverage, Aptevo's positive progress in its oncology pipeline provides potential upside. The biotechnology industry is highly volatile and requires caution Datavault AI pre-market up 38.69%. No recent news

### Related Stocks

- [CHEK.US](https://longbridge.com/en/quote/CHEK.US.md)
- [CHOW.US](https://longbridge.com/en/quote/CHOW.US.md)
- [MBAI.US](https://longbridge.com/en/quote/MBAI.US.md)

## Related News & Research

- [Check-Cap sets post-merger board committee lineup for MBody AI deal](https://longbridge.com/en/news/296398107.md)
- [ChowChow Cloud prices US$500,000 private placement at US$0.58 per share](https://longbridge.com/en/news/290198563.md)
- [Check-Cap Highlights MBody AI’s Expanded Fortune 500 Robotics Deployment Ahead of Merger](https://longbridge.com/en/news/281235217.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**